The World Health Organization (WHO) and its partners are calling on governments and other stakeholders to accelerate the implementation of the novel, 6-month all-oral regimen for the treatment of drug-resistant tuberculosis. This Call to Action highlights WHO’s latest guidelines on drug-resistant TB treatment recommend rapid roll-out of the novel BPaLM/BPaL regimen that has the potential to dramatically increase cure rates due to its high efficacy, allow broader access due to its lower cost and improve patient quality of life as this regimen is all-oral and significantly shorter than conventional treatment regimens.
|